{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:42:45Z","timestamp":1787877765336,"version":"build-2784847793"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40256-024-00688-8","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:01:54Z","timestamp":1728651714000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vitamin D\u2013Parathyroid Hormone\u2013Fibroblast Growth Factor 23 Axis and Cardiac Remodeling"],"prefix":"10.1007","volume":"25","author":[{"given":"Cuiyun","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-7243","authenticated-orcid":false,"given":"Yihang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"issue":"10","key":"688_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/cells8101128","volume":"8","author":"D Sch\u00fcttler","year":"2019","unstructured":"Sch\u00fcttler D, Clauss S, Weckbach LT, Brunner S. Molecular mechanisms of cardiac remodeling and regeneration in physical exercise. Cells. 2019;8(10):1128. https:\/\/doi.org\/10.3390\/cells8101128.","journal-title":"Cells"},{"issue":"4","key":"688_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","volume":"119","author":"PS Jhund","year":"2009","unstructured":"Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.812172.","journal-title":"Circulation"},{"issue":"3","key":"688_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","volume":"72","author":"A Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez A, Ravassa S, L\u00f3pez B, et al. Myocardial remodeling in hypertension. Hypertension. 2018;72(3):549\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11125.","journal-title":"Hypertension"},{"issue":"3","key":"688_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/toxins12030161","volume":"12","author":"N Kaesler","year":"2020","unstructured":"Kaesler N, Babler A, Floege J, Kramann R. Cardiac remodeling in chronic kidney disease. Toxins (Basel). 2020;12(3):161. https:\/\/doi.org\/10.3390\/toxins12030161.","journal-title":"Toxins (Basel)."},{"issue":"4","key":"688_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11897-011-0070-8","volume":"8","author":"H von Bibra","year":"2011","unstructured":"von Bibra H, St John Sutton M. Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep. 2011;8(4):242\u201351. https:\/\/doi.org\/10.1007\/s11897-011-0070-8.","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"688_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/cphy.c140071","volume":"6","author":"SJ Khundmiri","year":"2016","unstructured":"Khundmiri SJ, Murray RD, Lederer EPTH, Vitamin D. PTH and Vitamin D. Compr Physiol. 2016;6(2):561\u2013601. https:\/\/doi.org\/10.1002\/cphy.c140071.","journal-title":"Compr Physiol"},{"key":"688_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fendo.2018.00351","volume":"9","author":"R St\u00f6hr","year":"2018","unstructured":"St\u00f6hr R, Schuh A, Heine GH, Brandenburg V. FGF23 in cardiovascular disease: innocent bystander or active mediator? [published correction appears in Front Endocrinol (Lausanne). 2018 Jul 18;9:422. 10.3389\/fendo.2018.00422]. Front Endocrinol (Lausanne). 2018;9:351. https:\/\/doi.org\/10.3389\/fendo.2018.00351.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"688_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2019.03.002","volume":"66","author":"C Fauconnier","year":"2019","unstructured":"Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D. FGF23: clinical usefulness and analytical evolution. Clin Biochem. 2019;66:1\u201312. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.03.002.","journal-title":"Clin Biochem"},{"issue":"2","key":"688_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","volume":"16","author":"JE Blau","year":"2015","unstructured":"Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015;16(2):165\u201374. https:\/\/doi.org\/10.1007\/s11154-015-9318-z.","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"688_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.numecd.2016.06.007","volume":"26","author":"A Zittermann","year":"2016","unstructured":"Zittermann A, Ernst JB. Calciotropic and phosphaturic hormones in heart failure. Nutr Metab Cardiovasc Dis. 2016;26(11):971\u20139. https:\/\/doi.org\/10.1016\/j.numecd.2016.06.007.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"688_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.numecd.2017.07.009","volume":"27","author":"C D'Amore","year":"2017","unstructured":"D\u2019Amore C, Marsico F, Parente A, et al. Vitamin D deficiency and clinical outcome in patients with chronic heart failure: A review. Nutr Metab Cardiovasc Dis. 2017;27(10):837\u201349. https:\/\/doi.org\/10.1016\/j.numecd.2017.07.009.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"688_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11897-017-0355-7","volume":"14","author":"DM Brinkley","year":"2017","unstructured":"Brinkley DM, Ali OM, Zalawadiya SK, Wang TJ. Vitamin D and heart failure [published correction appears in Curr Heart Fail Rep. 2018 Aug;15(4):280. 10.1007\/s11897-018-0394-8]. Curr Heart Fail Rep. 2017;14(5):410\u201320. https:\/\/doi.org\/10.1007\/s11897-017-0355-7.","journal-title":"Curr Heart Fail Rep"},{"issue":"3","key":"688_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266\u201381. https:\/\/doi.org\/10.1056\/NEJMra070553.","journal-title":"N Engl J Med"},{"issue":"7","key":"688_CR14","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2011 Dec;96(12):3908] [published correction appears in J Clin Endocrinol Metab. 2024 Jun 05:dgae373. 10.1210\/clinem\/dgae373]. J Clin Endocrinol Metab. 2011;96(7):1911\u201330. https:\/\/doi.org\/10.1210\/jc.2011-0385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"688_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.abb.2012.04.001","volume":"523","author":"Y Wang","year":"2012","unstructured":"Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys. 2012;523(1):123\u201333. https:\/\/doi.org\/10.1016\/j.abb.2012.04.001.","journal-title":"Arch Biochem Biophys"},{"issue":"4423","key":"688_CR16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.505004","volume":"206","author":"WE Stumpf","year":"1979","unstructured":"Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206(4423):1188\u201390. https:\/\/doi.org\/10.1126\/science.505004.","journal-title":"Science"},{"issue":"1 Pt 1","key":"688_CR17","doi-asserted-by":"publisher","first-page":"E134","DOI":"10.1152\/ajpendo.1990.258.1.E134","volume":"258","author":"RE Weishaar","year":"1990","unstructured":"Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol. 1990;258(1 Pt 1):E134\u201342. https:\/\/doi.org\/10.1152\/ajpendo.1990.258.1.E134.","journal-title":"Am J Physiol"},{"issue":"3\u20135","key":"688_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jsbmb.2006.12.081","volume":"103","author":"A Rahman","year":"2007","unstructured":"Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103(3\u20135):416\u20139. https:\/\/doi.org\/10.1016\/j.jsbmb.2006.12.081.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"688_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1172\/JCI31044","volume":"117","author":"BC Berk","year":"2007","unstructured":"Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117(3):568\u201375. https:\/\/doi.org\/10.1172\/JCI31044.","journal-title":"J Clin Invest"},{"issue":"3","key":"688_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/cvr\/cvn261","volume":"81","author":"KT Weber","year":"2009","unstructured":"Weber KT, Weglicki WB, Simpson RU. Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res. 2009;81(3):500\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvn261.","journal-title":"Cardiovasc Res"},{"issue":"3\u20134","key":"688_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/1074248410390214","volume":"16","author":"M Agarwal","year":"2011","unstructured":"Agarwal M, Phan A, Willix R Jr, Barber M, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther. 2011;16(3\u20134):354\u201363. https:\/\/doi.org\/10.1177\/1074248410390214.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"688_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/08037051.2019.1645587","volume":"29","author":"LF Gafane-Matemane","year":"2020","unstructured":"Gafane-Matemane LF, Mokae NL, Breet Y, Malan L. Relation of the renin-angiotensin-aldosterone system with potential cardiac injury and remodelling: the SABPA study. Blood Press. 2020;29(1):31\u20138. https:\/\/doi.org\/10.1080\/08037051.2019.1645587.","journal-title":"Blood Press"},{"issue":"1\u20135","key":"688_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jsbmb.2004.03.004","volume":"89\u201390","author":"YC Li","year":"2004","unstructured":"Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89\u201390(1\u20135):387\u201392. https:\/\/doi.org\/10.1016\/j.jsbmb.2004.03.004.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"688_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neulet.2015.01.013","volume":"588","author":"W Zhang","year":"2015","unstructured":"Zhang W, Chen L, Zhang L, et al. Administration of exogenous 1,25(OH)2D3 normalizes overactivation of the central renin-angiotensin system in 1\u03b1(OH)ase knockout mice. Neurosci Lett. 2015;588:184\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2015.01.013.","journal-title":"Neurosci Lett"},{"issue":"1","key":"688_CR25","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1152\/ajpendo.00224.2004","volume":"288","author":"W Xiang","year":"2005","unstructured":"Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):E125\u201332. https:\/\/doi.org\/10.1152\/ajpendo.00224.2004.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"688_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ki.2008.101","volume":"74","author":"C Zhou","year":"2008","unstructured":"Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170\u20139. https:\/\/doi.org\/10.1038\/ki.2008.101.","journal-title":"Kidney Int"},{"key":"688_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3389\/fphys.2019.01118","volume":"10","author":"SM Grundmann","year":"2019","unstructured":"Grundmann SM, Schutkowski A, Schreier B, et al. Vitamin D receptor deficiency does not affect blood pressure and heart function. Front Physiol. 2019;10:1118. https:\/\/doi.org\/10.3389\/fphys.2019.01118.","journal-title":"Front Physiol"},{"issue":"3","key":"688_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00395-019-0722-5","volume":"114","author":"L Bacmeister","year":"2019","unstructured":"Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3):19. https:\/\/doi.org\/10.1007\/s00395-019-0722-5.","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"688_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10741-018-9716-x","volume":"23","author":"M Bartekova","year":"2018","unstructured":"Bartekova M, Radosinska J, Jelemensky M, Dhalla NS. Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev. 2018;23(5):733\u201358. https:\/\/doi.org\/10.1007\/s10741-018-9716-x.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"688_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41598-018-19708-0","volume":"8","author":"AJ Rodriguez","year":"2018","unstructured":"Rodriguez AJ, Mousa A, Ebeling PR, Scott D, de Courten B. Effects of vitamin D supplementation on inflammatory markers in heart failure: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):1169. https:\/\/doi.org\/10.1038\/s41598-018-19708-0.","journal-title":"Sci Rep"},{"key":"688_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/547697","volume":"2015","author":"YH Ma","year":"2015","unstructured":"Ma YH, Zhou YL, Yue CY, et al. Vitamin D deficiency contributes to the reduction and impaired function of na\u00efve CD45RA\u207a regulatory T cell in chronic heart failure. J Immunol Res. 2015;2015: 547697. https:\/\/doi.org\/10.1155\/2015\/547697.","journal-title":"J Immunol Res"},{"issue":"3","key":"688_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4065\/81.3.353","volume":"81","author":"MF Holick","year":"2006","unstructured":"Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353\u201373. https:\/\/doi.org\/10.4065\/81.3.353.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"688_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.numecd.2010.01.002","volume":"20","author":"P Ameri","year":"2010","unstructured":"Ameri P, Ronco D, Casu M, et al. High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis. 2010;20(9):633\u201340. https:\/\/doi.org\/10.1016\/j.numecd.2010.01.002.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"688_CR34","doi-asserted-by":"publisher","first-page":"744","DOI":"10.5152\/akd.2014.5637","volume":"15","author":"T \u015eeker","year":"2015","unstructured":"\u015eeker T, G\u00fcr M, U\u00e7ar H, et al. Lower serum 25-hydroxyvitamin D level is associated with impaired myocardial performance and left ventricle hypertrophy in newly diagnosed hypertensive patients. Anatol J Cardiol. 2015;15(9):744\u201350. https:\/\/doi.org\/10.5152\/akd.2014.5637.","journal-title":"Anatol J Cardiol"},{"issue":"9","key":"688_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/eurjhf\/hfs091","volume":"14","author":"T Fall","year":"2012","unstructured":"Fall T, Shiue I, Berge\u00e5 af Geijerstam P, et al. Relations of circulating vitamin D concentrations with left ventricular geometry and function. Eur J Heart Fail. 2012;14(9):985\u201391. https:\/\/doi.org\/10.1093\/eurjhf\/hfs091.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"688_CR36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/life13020372","volume":"13","author":"AC Hag\u0103u","year":"2023","unstructured":"Hag\u0103u AC, Pu\u0219ca\u0219 A, Tog\u0103nel R, Muntean I. Is Hypovitaminosis D a Risk Factor for Heart Failure? Life (Basel). 2023;13(2):372. https:\/\/doi.org\/10.3390\/life13020372.","journal-title":"Life (Basel)."},{"issue":"5","key":"688_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2337\/dc11-1944","volume":"35","author":"S Parikh","year":"2012","unstructured":"Parikh S, Guo DH, Pollock NK, et al. Circulating 25-hydroxyvitamin D concentrations are correlated with cardiometabolic risk among American black and white adolescents living in a year-round sunny climate. Diabetes Care. 2012;35(5):1133\u20138. https:\/\/doi.org\/10.2337\/dc11-1944.","journal-title":"Diabetes Care"},{"issue":"2","key":"688_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.20960\/nh.03291","volume":"38","author":"RCS Dantas-Komatsu","year":"2021","unstructured":"Dantas-Komatsu RCS, Freire FLA, de Lira NRD, et al. Vitamin D status and predictors of 25-hydroxyvitamin D levels in patients with heart failure living in a sunny region. Estado de la vitamina D y predictores de los niveles de 25-hidroxivitamina D en pacientes con insuficiencia card\u00edaca residentes en una regi\u00f3n soleada. Nutr Hosp. 2021;38(2):349\u201357. https:\/\/doi.org\/10.20960\/nh.03291.","journal-title":"Nutr Hosp"},{"issue":"22","key":"688_CR39","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.jacc.2016.03.508","volume":"67","author":"KK Witte","year":"2016","unstructured":"Witte KK, Byrom R, Gierula J, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE Study. J Am Coll Cardiol. 2016;67(22):2593\u2013603. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.508.","journal-title":"J Am Coll Cardiol"},{"key":"688_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2019.01.027","volume":"280","author":"A Zittermann","year":"2019","unstructured":"Zittermann A, Ernst JB, Prokop S, et al. Vitamin D supplementation of 4000 IU daily and cardiac function in patients with advanced heart failure: The EVITA trial. Int J Cardiol. 2019;280:117\u201323. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.027.","journal-title":"Int J Cardiol"},{"issue":"4","key":"688_CR41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/HYPERTENSIONAHA.113.02177","volume":"63","author":"MD Witham","year":"2014","unstructured":"Witham MD, Ireland S, Houston JG, et al. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension. 2014;63(4):706\u201312. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02177.","journal-title":"Hypertension"},{"issue":"1","key":"688_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/CIRCHEARTFAILURE.114.001738","volume":"8","author":"MM Donneyong","year":"2015","unstructured":"Donneyong MM, Hornung CA, Taylor KC, et al. Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women\u2019s health initiative. Circ Heart Fail. 2015;8(1):49\u201356. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001738.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"688_CR43","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamacardio.2017.0175","volume":"2","author":"R Scragg","year":"2017","unstructured":"Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin d assessment study: a randomized clinical trial. JAMA Cardiol. 2017;2(6):608\u201316. https:\/\/doi.org\/10.1001\/jamacardio.2017.0175.","journal-title":"JAMA Cardiol."},{"issue":"6","key":"688_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40256-019-00357-1","volume":"19","author":"M Wu","year":"2019","unstructured":"Wu M, Xu K, Wu Y, Lin L. Role of vitamin D in patients with heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2019;19(6):541\u201352. https:\/\/doi.org\/10.1007\/s40256-019-00357-1.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"688_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31083\/j.rcm2404111","volume":"24","author":"PS Tappia","year":"2023","unstructured":"Tappia PS, Lopez R, Fitzpatrick-Wong S, Ramjiawan B. Understanding the role of vitamin D in heart failure. Rev Cardiovasc Med. 2023;24(4):111. https:\/\/doi.org\/10.31083\/j.rcm2404111.","journal-title":"Rev Cardiovasc Med"},{"issue":"5","key":"688_CR46","first-page":"517","volume":"19","author":"S Moghassemi","year":"2014","unstructured":"Moghassemi S, Marjani A. The effect of short-term vitamin D supplementation on lipid profile and blood pressure in post-menopausal women: A randomized controlled trial. Iran J Nurs Midwifery Res. 2014;19(5):517\u201321.","journal-title":"Iran J Nurs Midwifery Res"},{"issue":"4","key":"688_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1017\/S000711451700397X","volume":"119","author":"FA Adebayo","year":"2018","unstructured":"Adebayo FA, Itkonen ST, \u00d6hman T, et al. Vitamin D intake, serum 25-hydroxyvitamin D status and response to moderate vitamin D3 supplementation: a randomised controlled trial in East African and Finnish women. Br J Nutr. 2018;119(4):431\u201341. https:\/\/doi.org\/10.1017\/S000711451700397X.","journal-title":"Br J Nutr"},{"issue":"6","key":"688_CR48","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00394-018-1775-1","volume":"58","author":"KD Cashman","year":"2019","unstructured":"Cashman KD, Ritz C, Adebayo FA, et al. Differences in the dietary requirement for vitamin D among Caucasian and East African women at Northern latitude. Eur J Nutr. 2019;58(6):2281\u201391. https:\/\/doi.org\/10.1007\/s00394-018-1775-1.","journal-title":"Eur J Nutr"},{"key":"688_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cca.2014.03.029","volume":"433","author":"D Gruson","year":"2014","unstructured":"Gruson D, Buglioni A, Burnett JC Jr. PTH: Potential role in management of heart failure. Clin Chim Acta. 2014;433:290\u20136. https:\/\/doi.org\/10.1016\/j.cca.2014.03.029.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"688_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11897-011-0048-6","volume":"8","author":"MD Witham","year":"2011","unstructured":"Witham MD. Vitamin D in chronic heart failure. Curr Heart Fail Rep. 2011;8(2):123\u201330. https:\/\/doi.org\/10.1007\/s11897-011-0048-6.","journal-title":"Curr Heart Fail Rep"},{"issue":"19","key":"688_CR51","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM197711102971906","volume":"297","author":"MR Haussler","year":"1977","unstructured":"Haussler MR, McCain TA. Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). N Engl J Med. 1977;297(19):1041\u201350. https:\/\/doi.org\/10.1056\/NEJM197711102971906.","journal-title":"N Engl J Med"},{"issue":"22","key":"688_CR52","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.ehj.2003.09.010","volume":"24","author":"FN Saleh","year":"2003","unstructured":"Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003;24(22):2054\u201360. https:\/\/doi.org\/10.1016\/j.ehj.2003.09.010.","journal-title":"Eur Heart J"},{"issue":"10","key":"688_CR53","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1681\/ASN.V4101814","volume":"4","author":"K Amann","year":"1994","unstructured":"Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994;4(10):1814\u20139. https:\/\/doi.org\/10.1681\/ASN.V4101814.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"688_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1365-2362.1998.00289.x","volume":"28","author":"G Hedb\u00e4ck","year":"1998","unstructured":"Hedb\u00e4ck G, Od\u00e9n A. Increased risk of death from primary hyperparathyroidism\u2013an update. Eur J Clin Invest. 1998;28(4):271\u20136. https:\/\/doi.org\/10.1046\/j.1365-2362.1998.00289.x.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"688_CR55","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/ndt\/gfm849","volume":"23","author":"ML Melamed","year":"2008","unstructured":"Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant. 2008;23(5):1650\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfm849.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"688_CR56","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurjhf\/hfq134","volume":"12","author":"E Hagstr\u00f6m","year":"2010","unstructured":"Hagstr\u00f6m E, Ingelsson E, Sundstr\u00f6m J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12(11):1186\u201392. https:\/\/doi.org\/10.1093\/eurjhf\/hfq134.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"688_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/1871530311313010012","volume":"13","author":"H Altay","year":"2013","unstructured":"Altay H, Colkesen Y. Parathyroid hormone and heart failure: novel biomarker strategy. Endocr Metab Immune Disord Drug Targets. 2013;13(1):100\u20134. https:\/\/doi.org\/10.2174\/1871530311313010012.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"688_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14797\/mdcj-13-2-49","volume":"13","author":"SJ Brown","year":"2017","unstructured":"Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Debakey Cardiovasc J. 2017;13(2):49\u201354. https:\/\/doi.org\/10.14797\/mdcj-13-2-49.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"688_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0008-6363(97)00194-6","volume":"37","author":"KD Schl\u00fcter","year":"1998","unstructured":"Schl\u00fcter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37(1):34\u201341. https:\/\/doi.org\/10.1016\/s0008-6363(97)00194-6.","journal-title":"Cardiovasc Res"},{"issue":"6 Pt 2","key":"688_CR60","doi-asserted-by":"publisher","first-page":"H1998","DOI":"10.1152\/ajpheart.1993.264.6.H1998","volume":"264","author":"M Smogorzewski","year":"1993","unstructured":"Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264(6 Pt 2):H1998\u20132006. https:\/\/doi.org\/10.1152\/ajpheart.1993.264.6.H1998.","journal-title":"Am J Physiol"},{"issue":"10","key":"688_CR61","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1210\/jcem.81.10.8855783","volume":"81","author":"A Grey","year":"1996","unstructured":"Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption\u2013a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3450\u20134. https:\/\/doi.org\/10.1210\/jcem.81.10.8855783.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"688_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","volume":"63","author":"A Tomaschitz","year":"2014","unstructured":"Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63(1):20\u201331. https:\/\/doi.org\/10.1016\/j.metabol.2013.08.016.","journal-title":"Metabolism"},{"issue":"4","key":"688_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-012-9336-9","volume":"18","author":"S Gandhi","year":"2013","unstructured":"Gandhi S, Myers RB. Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev. 2013;18(4):465\u201373. https:\/\/doi.org\/10.1007\/s10741-012-9336-9.","journal-title":"Heart Fail Rev"},{"issue":"Suppl4","key":"688_CR64","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.4103\/2230-8210.86979","volume":"15 Suppl 4","author":"S Chopra","year":"2011","unstructured":"Chopra S, Cherian D, Jacob JJ. The thyroid hormone, parathyroid hormone and vitamin D associated hypertension. Indian J Endocrinol Metab. 2011;15 Suppl 4(Suppl4):S354\u201360. https:\/\/doi.org\/10.4103\/2230-8210.86979.","journal-title":"Indian J Endocrinol Metab."},{"issue":"1","key":"688_CR65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/endo-129-1-489","volume":"129","author":"CM Isales","year":"1991","unstructured":"Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129(1):489\u201395. https:\/\/doi.org\/10.1210\/endo-129-1-489.","journal-title":"Endocrinology"},{"issue":"2","key":"688_CR66","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1152\/ajpendo.2001.280.2.E209","volume":"280","author":"G Mazzocchi","year":"2001","unstructured":"Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280(2):E209\u201313. https:\/\/doi.org\/10.1152\/ajpendo.2001.280.2.E209.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"688_CR67","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","volume":"31","author":"A Tomaschitz","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, M\u00e4rz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31(10):1237\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehq019.","journal-title":"Eur Heart J"},{"issue":"2","key":"688_CR68","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1210\/jc.2014-3949","volume":"100","author":"J Brown","year":"2015","unstructured":"Brown J, de Boer IH, Robinson-Cohen C, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490\u20139. https:\/\/doi.org\/10.1210\/jc.2014-3949.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"688_CR69","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jch.13064","volume":"19","author":"J Wetzel","year":"2017","unstructured":"Wetzel J, Pilz S, Gr\u00fcbler MR, et al. Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial. J Clin Hypertens (Greenwich). 2017;19(11):1173\u201380. https:\/\/doi.org\/10.1111\/jch.13064.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"688_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01060.","journal-title":"Hypertension"},{"issue":"4","key":"688_CR71","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/eje.0.1470453","volume":"147","author":"V Nuzzo","year":"2002","unstructured":"Nuzzo V, Tauchmanov\u00e0 L, Fonderico F, et al. Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol. 2002;147(4):453\u20139. https:\/\/doi.org\/10.1530\/eje.0.1470453.","journal-title":"Eur J Endocrinol"},{"key":"688_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/408295","volume":"2012","author":"P Luigi","year":"2012","unstructured":"Luigi P, Chiara FM, Laura Z, et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int J Endocrinol. 2012;2012: 408295. https:\/\/doi.org\/10.1155\/2012\/408295.","journal-title":"Int J Endocrinol."},{"issue":"12","key":"688_CR73","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1210\/jc.2015-3202","volume":"100","author":"DJ McMahon","year":"2015","unstructured":"McMahon DJ, Carrelli A, Palmeri N, et al. Effect of parathyroidectomy upon left ventricular mass in primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab. 2015;100(12):4399\u2013407. https:\/\/doi.org\/10.1210\/jc.2015-3202.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"688_CR74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jash.2015.06.020","volume":"9","author":"AA Soares","year":"2015","unstructured":"Soares AA, Freitas WM, Japiass\u00fa AV, et al. Enhanced parathyroid hormone levels are associated with left ventricle hypertrophy in very elderly men and women. J Am Soc Hypertens. 2015;9(9):697\u2013704. https:\/\/doi.org\/10.1016\/j.jash.2015.06.020.","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"688_CR75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12603-015-0649-y","volume":"20","author":"\u00c1 Ace\u00f1a","year":"2016","unstructured":"Ace\u00f1a \u00c1, Pello AM, Carda R, et al. Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease. J Nutr Health Aging. 2016;20(6):659\u201364. https:\/\/doi.org\/10.1007\/s12603-015-0649-y.","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"688_CR76","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1210\/jc.2009-2072","volume":"95","author":"MD Walker","year":"2010","unstructured":"Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(5):2172\u20139. https:\/\/doi.org\/10.1210\/jc.2009-2072.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"688_CR77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59820","volume":"16","author":"KSS Amaravadi","year":"2024","unstructured":"Amaravadi KSS, Nalisetty P, Vadlamani N, et al. Impact of elevated fibroblast growth factor 23 (FGF23) on the cardiovascular system: a comprehensive systematic literature review. Cureus. 2024;16(5): e59820. https:\/\/doi.org\/10.7759\/cureus.59820.","journal-title":"Cureus."},{"issue":"4","key":"688_CR78","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/ejhf.1424","volume":"21","author":"BA Bergmark","year":"2019","unstructured":"Bergmark BA, Udell JA, Morrow DA, et al. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. Eur J Heart Fail. 2019;21(4):462\u201370. https:\/\/doi.org\/10.1002\/ejhf.1424.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"688_CR79","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120\u20133. https:\/\/doi.org\/10.1074\/jbc.C500457200.","journal-title":"J Biol Chem"},{"key":"688_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fcell.2016.00110","volume":"4","author":"N Itoh","year":"2016","unstructured":"Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol. 2016;4:110. https:\/\/doi.org\/10.3389\/fcell.2016.00110.","journal-title":"Front Cell Dev Biol."},{"issue":"7120","key":"688_CR81","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770\u20134. https:\/\/doi.org\/10.1038\/nature05315.","journal-title":"Nature"},{"key":"688_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2016.10.001","volume":"100","author":"C Faul","year":"2017","unstructured":"Faul C. Cardiac actions of fibroblast growth factor 23. Bone. 2017;100:69\u201379. https:\/\/doi.org\/10.1016\/j.bone.2016.10.001.","journal-title":"Bone"},{"issue":"12","key":"688_CR83","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1172\/JCI32409","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117(12):4003\u20138. https:\/\/doi.org\/10.1172\/JCI32409.","journal-title":"J Clin Invest"},{"issue":"6","key":"688_CR84","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/0092-8674(94)90032-9","volume":"79","author":"T Spivak-Kroizman","year":"1994","unstructured":"Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994;79(6):1015\u201324. https:\/\/doi.org\/10.1016\/0092-8674(94)90032-9.","journal-title":"Cell"},{"issue":"1","key":"688_CR85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kint.2018.03.024","volume":"94","author":"C Faul","year":"2018","unstructured":"Faul C. FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int. 2018;94(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kint.2018.03.024.","journal-title":"Kidney Int"},{"issue":"8","key":"688_CR86","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","volume":"82","author":"R Nehgme","year":"1997","unstructured":"Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 1997;82(8):2450\u20134. https:\/\/doi.org\/10.1210\/jcem.82.8.4181.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"688_CR87","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584\u201392. https:\/\/doi.org\/10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"},{"issue":"7","key":"688_CR88","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","volume":"31","author":"M Leifheit-Nestler","year":"2016","unstructured":"Leifheit-Nestler M, Gro\u00dfe Siemer R, Flasbart K, et al. Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31(7):1088\u201399. https:\/\/doi.org\/10.1093\/ndt\/gfv421.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"688_CR89","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. https:\/\/doi.org\/10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"issue":"6","key":"688_CR90","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.002.","journal-title":"Cell Metab"},{"issue":"40","key":"688_CR91","doi-asserted-by":"publisher","first-page":"64649","DOI":"10.18632\/oncotarget.11623","volume":"7","author":"H Hao","year":"2016","unstructured":"Hao H, Li X, Li Q, et al. FGF23 promotes myocardial fibrosis in mice through activation of \u03b2-catenin. Oncotarget. 2016;7(40):64649\u201364. https:\/\/doi.org\/10.18632\/oncotarget.11623.","journal-title":"Oncotarget"},{"issue":"4","key":"688_CR92","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600\u20136. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.10.033.","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"688_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231905","volume":"15","author":"K Kuga","year":"2020","unstructured":"Kuga K, Kusakari Y, Uesugi K, et al. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-\u03b21. PLoS ONE. 2020;15(4): e0231905. https:\/\/doi.org\/10.1371\/journal.pone.0231905.","journal-title":"PLoS ONE"},{"issue":"1","key":"688_CR94","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1038\/s41598-017-10140-4","volume":"7","author":"S Slavic","year":"2017","unstructured":"Slavic S, Ford K, Modert M, et al. Genetic ablation of Fgf23 or klotho does not modulate experimental heart hypertrophy induced by pressure overload. Sci Rep. 2017;7(1):11298. https:\/\/doi.org\/10.1038\/s41598-017-10140-4.","journal-title":"Sci Rep"},{"issue":"3","key":"688_CR95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MED.0000000000000062","volume":"21","author":"JM Brown","year":"2014","unstructured":"Brown JM, Vaidya A. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):193\u2013201. https:\/\/doi.org\/10.1097\/MED.0000000000000062.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"688_CR96","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/ehf2.12816","volume":"7","author":"C Roy","year":"2020","unstructured":"Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7(5):2494\u2013507. https:\/\/doi.org\/10.1002\/ehf2.12816.","journal-title":"ESC Heart Fail."},{"issue":"12","key":"688_CR97","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/toxins8120369","volume":"8","author":"P Kuczera","year":"2016","unstructured":"Kuczera P, Adamczak M, Wiecek A. Fibroblast growth factor-23-a potential uremic toxin. Toxins (Basel). 2016;8(12):369. https:\/\/doi.org\/10.3390\/toxins8120369.","journal-title":"Toxins (Basel)."},{"key":"688_CR98","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fendo.2018.00278","volume":"9","author":"M Leifheit-Nestler","year":"2018","unstructured":"Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol (Lausanne). 2018;9:278. https:\/\/doi.org\/10.3389\/fendo.2018.00278.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"688_CR99","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543\u201353. https:\/\/doi.org\/10.1172\/JCI61405.","journal-title":"J Clin Invest"},{"issue":"22","key":"688_CR100","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","volume":"63","author":"JA Udell","year":"2014","unstructured":"Udell JA, Morrow DA, Jarolim P, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014;63(22):2421\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.026.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"688_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013876.","journal-title":"Circulation"},{"issue":"8","key":"688_CR102","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","volume":"304","author":"CD Touchberry","year":"2013","unstructured":"Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013;304(8):E863\u201373. https:\/\/doi.org\/10.1152\/ajpendo.00596.2012.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3\u20135","key":"688_CR103","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","volume":"103","author":"TK Barthel","year":"2007","unstructured":"Barthel TK, Mathern DR, Whitfield GK, et al. 1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007;103(3\u20135):381\u20138. https:\/\/doi.org\/10.1016\/j.jsbmb.2006.12.054.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"688_CR104","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bj\u00f6rklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195(1):125\u201331. https:\/\/doi.org\/10.1677\/JOE-07-0267.","journal-title":"J Endocrinol"},{"issue":"6","key":"688_CR105","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/ki.2014.215","volume":"86","author":"T Meir","year":"2014","unstructured":"Meir T, Durlacher K, Pan Z, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014;86(6):1106\u201315. https:\/\/doi.org\/10.1038\/ki.2014.215.","journal-title":"Kidney Int"},{"issue":"1","key":"688_CR106","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00223-020-00686-3","volume":"108","author":"M Peacock","year":"2021","unstructured":"Peacock M. Phosphate Metabolism in Health and Disease. Calcif Tissue Int. 2021;108(1):3\u201315. https:\/\/doi.org\/10.1007\/s00223-020-00686-3.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"688_CR107","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.bbrc.2005.01.033","volume":"328","author":"T J\u00e4\u00e4skel\u00e4inen","year":"2005","unstructured":"J\u00e4\u00e4skel\u00e4inen T, Huhtakangas J, M\u00e4enp\u00e4\u00e4 PH. Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y. Biochem Biophys Res Commun. 2005;328(4):831\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2005.01.033.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"688_CR108","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","volume":"58","author":"JH Ix","year":"2011","unstructured":"Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011;58(5):737\u201345. https:\/\/doi.org\/10.1053\/j.ajkd.2011.06.011.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"688_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","volume":"3","author":"BA Bergmark","year":"2018","unstructured":"Bergmark BA, Udell JA, Morrow DA, et al. Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2018;3(6):473\u201380. https:\/\/doi.org\/10.1001\/jamacardio.2018.0653.","journal-title":"JAMA Cardiol."},{"issue":"4 Suppl 5","key":"688_CR110","first-page":"S5","volume":"15","author":"A Zadshir","year":"2005","unstructured":"Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis. 2005;15(4 Suppl 5):S5-101.","journal-title":"Ethn Dis"},{"issue":"2","key":"688_CR111","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4158\/EP.12.2.137","volume":"12","author":"JF Aloia","year":"2006","unstructured":"Aloia JF, Feuerman M, Yeh JK. Reference range for serum parathyroid hormone. Endocr Pract. 2006;12(2):137\u201344. https:\/\/doi.org\/10.4158\/EP.12.2.137.","journal-title":"Endocr Pract"},{"issue":"6","key":"688_CR112","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001278","volume":"3","author":"N Bansal","year":"2014","unstructured":"Bansal N, Zelnick L, Robinson-Cohen C, et al. Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2014;3(6): e001278. https:\/\/doi.org\/10.1161\/JAHA.114.001278.","journal-title":"J Am Heart Assoc"},{"key":"688_CR113","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12902.10.1111\/eci.12902","author":"JA Navarro-Garc\u00eda","year":"2018","unstructured":"Navarro-Garc\u00eda JA, Fern\u00e1ndez-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. Eur J Clin Invest. 2018. https:\/\/doi.org\/10.1111\/eci.12902.10.1111\/eci.12902.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"688_CR114","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfr384","volume":"27","author":"M Koizumi","year":"2012","unstructured":"Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27(2):784\u201390. https:\/\/doi.org\/10.1093\/ndt\/gfr384.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"688_CR115","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.03270314","volume":"10","author":"SM Sprague","year":"2015","unstructured":"Sprague SM, Wetmore JB, Gurevich K, et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2015;10(6):1021\u201330. https:\/\/doi.org\/10.2215\/CJN.03270314.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00688-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00688-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00688-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T05:07:25Z","timestamp":1738127245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00688-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00688-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"26 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cuiyun Deng and Yihang Wu declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Cuiyun Deng: Writing\u2014original draft. Yihang Wu: Validation; writing \u2013 review and editing. All authors have read and approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Data sharing not applicable to this review article as no datasets were generated.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}